Outpatient treatment for malignant pleural effusion using talc pleurodesis
Can Talc Pleurodesis for Malignant Pleural Effusion be Performed on an Ambulatory Basis
NA · North Tees and Hartlepool NHS Foundation Trust · NCT06682936
This study is testing if a new outpatient treatment using talc pleurodesis can help people with malignant pleural effusion feel better while spending less time in the hospital.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | North Tees and Hartlepool NHS Foundation Trust (other) |
| Locations | 1 site (Stockton-on-Tees, County Durham) |
| Trial ID | NCT06682936 on ClinicalTrials.gov |
What this trial studies
This study investigates the feasibility of performing talc pleurodesis for malignant pleural effusion on an outpatient basis, aiming to improve patient quality of life by reducing hospital stay. Eligible patients will undergo a chest drain procedure followed by talc slurry instillation, with the entire process designed to be completed in an ambulatory setting. The study will assess the deliverability of this protocol and gather patient feedback on its acceptability and effectiveness. The goal is to provide a less burdensome treatment option for patients with significant symptom burden and limited life expectancy.
Who should consider this trial
Good fit: Ideal candidates include patients with malignant pleural effusion who have a life expectancy greater than 30 days and a WHO performance status of 1-2.
Not a fit: Patients who have previously experienced a failed pleurodesis on the affected side or have a known non-expansile lung may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the quality of life for patients by minimizing hospital stays and associated complications.
How similar studies have performed: While the concept of outpatient pleurodesis is promising, this specific approach is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Malignant pleural effusion * Life expectancy \>30 days * WHO PS 1-2 (3 if due to dyspnoea) Exclusion Criteria: * Previous failed pleurodesis (on affected side) * Known non-expansile lung
Where this trial is running
Stockton-on-Tees, County Durham
- North Tees and Hartlepool NHS foundation trust — Stockton-on-Tees, County Durham, United Kingdom (RECRUITING)
Study contacts
- Principal investigator: Kevin Conroy, MBBS, FRCP — University Hospital of North Tees
- Study coordinator: Kevin Conroy, MBBS, FRCP
- Email: kevin.conroy@nhs.net
- Phone: 01642624615
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Malignant Pleural Effusion, Malignancy, Palliative Care, malignant pleural effusion, malignancy, palliative care